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To the Editor:
MET abnormalities, including 
overexpression, amplification, and 
mutation, have been described in non-
small-cell lung cancer (NSCLC). Ou 
et al.1 reported in Journal of Thoracic 
Oncology in 2011 a patient with de 
novo MET amplification and a rapid 
and durable response to the oral ALK 
and MET inhibitor, crizotinib. The util-
ity of MET amplification as a predic-
tive marker was recently confirmed in 
a larger case series, but there have been 
no data regarding the clinical signifi-
cance of MET mutations in NSCLC.
We treated a 76-year-old female 
diagnosed with metastatic squamous 
cell carcinoma of the lung in April 
2014. She was a former light smoker 
and quit tobacco use more than 30 years 
ago. Extended mutation analysis was 
performed, revealing a MET D1010H 
mutation and MDM2 amplification 
(Foundation Medicine, Cambridge, 
MA). She was initially treated with a 
combination of a novel MMP9 inhibi-
tor, carboplatin, and paclitaxel and had 
progressive disease after three cycles. 
Treatment was then changed to gem-
citabine, but after one cycle symptom-
atic disease progression occurred in 
the lung and bone and at a painful right 
It is uncommon for low-grade adeno-
carcinomas to present in such a way and 
are therefore under-represented in this 
study. This is reflected in the number 
of patients with an indeterminate pri-
mary tumor SUVmax; only 15 of 509 
patients had a primary tumor SUVmax 
less than 4.0, and just four patients had 
an SUVmax less than 2.5. From these 
15 patients, 11 patients had both inde-
terminate FDG avidity in the primary 
tumor and indeterminate avidity in the 
lymph nodes sampled by EBUS-TBNA. 
Ten of these tumors were adenocarcino-
mas plus one non-small-cell lung can-
cer not otherwise specified. The SUV 
ratio in all of the sampled lymph nodes 
was greater than 40% and ranged from 
45% to 175%. In three cases, EBUS-
TBNA confirmed N2/3 metastases. In 
the remaining eight cases, in which the 
EBUS-TBNA was negative, there were 
two false-negatives where nodal metas-
tases were subsequently diagnosed and 
six true-negatives. The risk stratification 
model indicated seven out of the eight 
cases of negative EBUS were high risk 
for false-negative sampling, suggesting 
the need for further pathological sam-
pling and two of seven were ultimately 
proven to be false-negative.
In summary, the SUV ratio does 
seem to be a useful indicator of the risk of 
nodal metastases in indeterminate FDG 
avidity tumors with indeterminate SUV 
FDG avidity in mediastinal lymph nodes. 
The risk stratification model, we presented 
in our study, therefore encompasses this 
clinical scenario and remains relevant 
to this patient group. We acknowledge 
the small number of such patients in our 
study and as such, our comments need be 
interpreted with this in mind. We would 
also stress the importance of using this 
risk stratification model for lymph nodes 
sampled with EBUS and deemed nega-
tive. It cannot replace pathological staging 
and has only been derived and validated 
in this setting.
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(SUV) ratio”; the ratio of maximum 
SUV between the primary tumor and 
mediastinal lymph nodes, on positron 
emission computed tomography (CT), 
in lung cancer patients. It was the previ-
ous work of Koksal et al. and Cerfolio 
et al. that sparked our own interest in 
the SUV ratio as a potential predictor 
of false-negative nodal sampling with 
endobronchial ultrasound-guided trans-
bronchial needle aspiration (EBUS-
TBNA). In our study, the SUV ratio 
proved to be a powerful predictor of 
nodal malignancy and false-negative 
EBUS-TBNA and is a key element of 
our risk stratification model.
Professor Koksal specifically asks 
about our experience with indeterminate 
18-F-fluorodeoxyglucose (FDG) avid-
ity tumors, for example, lepidic-type 
adenocarcinomas, and the usefulness 
of the SUV ratio in such circumstances. 
We use the term “indeterminate” to 
describe an SUVmax above that of the 
background mediastinal blood pool but 
lacking the significant FDG avidity nor-
mally associated with malignancy. Our 
first comment is that, in our experience, 
it is rare to undertake EBUS mediasti-
nal staging in such circumstances. Low-
grade adenocarcinomas are usually 
peripheral ground-glass opacities on CT 
imaging with no or indeterminate FDG 
uptake and normal hilar and mediastinal 
nodes radiologically. These tumors are 
often biologically indolent tumors, and 
therefore, nodal spread is less common. 
As per the American College of Chest 
Physicians Staging Guidelines,1 periph-
eral tumors with low or indeterminate 
FDG avidity and normal hilar/mediasti-
nal nodes radiologically do not require 
pathological nodal staging and can 
proceed directly to resection, assuming 
adequate fitness because the prevalence 
of nodal metastases is low. The preva-
lence of nodal metastases in our study 
was much higher as it predominantly 
included patients with N2/3 nodal dis-
ease on CT (376 of 509 patients, 74%). 
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True MET amplification (defined as an 
increase in the MET/CEP7 signal ratio) 
is significantly more rare, reported to be 
1% to 11%.3,4 Camidge et al.5 reported in 
2014 responses with crizotinib therapy in 
patients, with the highest response rates for 
tumors that had high amplification (MET/
CEP7 ratio ≥5). The incidence of MET-
mutations in NSCLC appears to be 1% to 
3%.3,4 We are not aware of any previous 
reports in the literature for MET-directed 
therapy in this population. Crizotinib is a 
well-tolerated treatment option, and further 
investigation of its antitumor effect in this 
setting is warranted. As we progress into the 
modern molecular age of NSCLC therapy, 
it will be important to identify regulatory 
and financial mechanisms to provide novel 
targeted agents to the appropriate patients.
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FIGURE 1.  Representative F-18 fluorodeoxyglucose-positron emission tomogra-
phy/CT coronal images at baseline and after 19 weeks of crizotinib therapy. Note 
the resolution of the large left lung primary lesion, small right lung nodule, and 
large right buttock mass. The muscle F-18 fluorodeoxyglucose-positron emission 
tomography activity on the follow-up scan is thought to be artifactual.
gluteal soft tissue mass. Treatment was 
initiated with crizotinib. She achieved 
a rapid improvement in her fatigue and 
complete resolution of pain. After 7 
weeks of therapy, computed tomogra-
phy imaging showed a reduction (64.4% 
by the Response Evaluation Criteria in 
Solid Tumors v 1.1) of the target lesions 
and resolution of numerous nontarget 
pulmonary nodules. The left upper lobe 
primary lung mass had reduced in size, 
measuring 38 by 24 mm (previously 49 
by 42 mm). The painful gluteal mass had 
shrunk from 54 by 36 mm to 14 by 8 mm. 
Additional imaging by F-18 fluorode-
oxyglucose-positron emission tomog-
raphy and computed tomography after 
19 weeks on treatment demonstrated a 
near complete response with resolution 
of all lesions except for the lung primary 
(now decreased to 29 by 16 mm) and a 
near F-18 fluorodeoxyglucose-positron 
emission tomography complete response 
(decrease in standard uptake value from 
20.4 to 2.1; Fig. 1). The patient has tol-
erated treatment well with a side effect 
profile consistent with crizotinib: mild 
taste changes, lower extremity edema, 
and vision changes at night.
Current therapy for NSCLC often 
employs nonspecific agents, such as 
cytotoxic chemotherapy with response 
rates of 20% to 35% in the first-line 
and less than 10% in pretreated disease. 
The field is moving toward a molecu-
lar age in which we identify driving 
mutations in a tumor sample and treat 
with a drug targeted to that specific 
abnormality. The major success sto-
ries so far have been with EGFR, ALK, 
and ROS mutant disease, and response 
rates of 60% to 80% are now frequently 
reported. Simultaneously, extended 
tumor mutation testing has become 
available for clinical use. In this setting, 
a rare mutation, sometimes of uncer-
tain significance, may be found. If an 
inhibitor directed against that mutation 
is available on or off of a research proto-
col, this may provide a novel treatment 
opportunity.
MET abnormalities of several kinds 
have been reported in NSCLC. Protein 
over-expression is found in 25% to 75% 
of NSCLC and has been associated with 
a poor prognosis.2 However, two phase III 
trials showed no benefit with MET-targeted 
therapy in molecularly unselected cohorts. 
University of California, Los Angeles
Santa Monica, California 
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